Download MendeleyDiscovery of triazine-benzimidazoles as selective inhibitors of mTOR.
Peterson, E.A., Andrews, P.S., Be, X., Boezio, A.A., Bush, T.L., Cheng, A.C., Coats, J.R., Colletti, A.E., Copeland, K.W., Dupont, M., Graceffa, R., Grubinska, B., Harmange, J.C., Kim, J.L., Mullady, E.L., Olivieri, P., Schenkel, L.B., Stanton, M.K., Teffera, Y., Whittington, D.A., Cai, T., La, D.S.(2011) Bioorg Med Chem Lett 21: 2064-2070
- PubMed: 21376583
- DOI: https://doi.org/10.1016/j.bmcl.2011.02.007
- Primary Citation of Related Structures:
3QAQ, 3QAR - PubMed Abstract:
mTOR is part of the PI3K/AKT pathway and is a central regulator of cell growth and survival. Since many cancers display mutations linked to the mTOR signaling pathway, mTOR has emerged as an important target for oncology therapy. Herein, we report the discovery of triazine benzimidazole inhibitors that inhibit mTOR kinase activity with up to 200-fold selectivity over the structurally homologous kinase PI3Kα. When tested in a panel of cancer cell lines displaying various mutations, a selective inhibitor from this series inhibited cellular proliferation with a mean IC(50) of 0.41 μM. Lead compound 42 demonstrated up to 83% inhibition of mTOR substrate phosphorylation in a murine pharmacodynamic model.
Organizational Affiliation:
Medicinal Chemistry, Amgen Inc, 360 Binney St, Cambridge, MA 02142, USA. epeterso@amgen.com
